Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Ponders Trimming PDUFA Programs

This article was originally published in The Tan Sheet

Executive Summary

Acting Commissioner Ostroff considers whether all aspects of the user fee program are delivering maximum added value.

You may also be interested in...



PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up

FDA wants to advance PRO projects through the user fee reauthorization, but ironically is having difficulty quantifying how much support it might need.

‘Breakthrough’ Fee Eyed As Deterrent To Frivolous Requests

Companies currently face little risk in seeking the designation because there is no financial cost and FDA denial is confidential.

FDA Staying The Course Under Ostroff; Hamburg’s Concerns Will Remain Focus

Acting FDA Commissioner says he can’t envision any new major priorities that would emerge in the short-term.

Related Content

Topics

UsernamePublicRestriction

Register

PS107795

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel